Canine brain tumor treatment.
Study details.
A novel surgical and targeted therapeutic approach to treat canine brain tumors.
Inclusion criteria:
- Be male or female and at least 12 months of age
- Weigh at least 5 kgs (11 pounds)
- Have Magnetic Resonance Imaging (MRI) demonstrating a spontaneous brain tumor consistent with glioma
- Have a life expectancy of at least 6 months
- The canine’s owner must demonstrate the ability to understand and the willingness to sign an informed consent document.
Exclusion criteria:
- Be pregnant, nursing, or intended for breeding during the study period
- Have a brain tumor that involves both hemispheres (and thus is not treatable), a caudal cranial fossa or brainstem tumor
- Be enrolled in another clinical treatment trial
- Have an active infection (within one week of enrollment)
- Have confirmation of significant systemic organ dysfunction that the investigator feels would place the dog at greater risk for study participation
- Have a history of allergic reactions to compounds or contraindications for MRI (allergy to
contrast, metal implants, or known adverse reaction to inhalation anesthesia)
Locations and contacts:
- Pittsburgh, PA: Edward Mackillop, DVM, DACVIM (Neurology) at 412.336.3400
Duration of study.
6 visits consisting of screening, surgery, and follow ups at 1, 3, and 6 months.
Covered costs.
All study-related costs including exams, diagnostics, and procedures are covered by the study sponsor.
